Product Description
InFlectis is developing a class of small molecules for the treatment of neuromuscular diseases. These are orally-available compounds intended to prolong the Integrated Stress Response (ISR) as a way to protect cells against the toxic effects of cellular stress. (Sourced from: https://inflectisbioscience.com/our-pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InFlectis BioScience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Multiple Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|